Abraxane News and Research

RSS
The U.S. Food and Drug Administration approved Abraxane for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in January 2005 for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within six months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated.
Genentech’s combination therapy improves outcome in patients with non-squamous non-small cell lung cancer

Genentech’s combination therapy improves outcome in patients with non-squamous non-small cell lung cancer

BeiGene collaborates with SpringWorks to evaluate new combinational therapy for solid tumors

BeiGene collaborates with SpringWorks to evaluate new combinational therapy for solid tumors